Economic analysis of epicup, an epigenetic test to predict the tissue of origin in cancer of unknown primary site.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e12532-e12532
Author(s):  
Carmen Balana ◽  
Alfredo Gracia ◽  
Lisette Kaskens ◽  
Sebastian Chiavenna ◽  
Xavier Matias-Guiu ◽  
...  
2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 4151-4151 ◽  
Author(s):  
G. R. Varadhachary ◽  
T. B. Edmonston ◽  
S. Karanth ◽  
H. R. Carlson ◽  
D. Lebanony ◽  
...  

Author(s):  
F. Anthony Greco

Cancer of unknown primary site (CUP) is a common heterogeneous clinicopathologic syndrome, but investigations and publications regarding these patients are rare. For the last 20 years, empiric “broad-spectrum” chemotherapy has been the standard therapy for the majority of these patients. More recently, improved immunocytochemistry and advent of gene-expression profiling have provided the diagnostic tools necessary to accurately define the tissue of origin in most patients. Molecular profiling assays complement standard pathologic diagnosis, and a recently reported large prospective study demonstrated an improvement in outcome for patients treated with site-specific therapy directed by the molecular assay diagnoses compared with empiric chemotherapy. Survival in molecularly diagnosed patients was as expected for those particular tumor types. The evaluation of patients has become more standardized. The empiric-chemotherapy era is ending and customized therapies based on accurate tissue of origin diagnoses have arrived. Eventually the recognition of the molecular aberrations responsible for the growth and metastasis of solid tumors, regardless of the tissue of origin, will lead to more precise and effective therapy for patients with advanced cancers.


2007 ◽  
Vol 22 (Suppl) ◽  
pp. S174 ◽  
Author(s):  
Hyung Il Kim ◽  
Sung Hoon Chung ◽  
Jun Eul Hwang ◽  
Sang Ho Kim ◽  
Jae Sook Ahn ◽  
...  

2018 ◽  
Vol 93 (6) ◽  
pp. 575-581
Author(s):  
Chan Keol Park ◽  
Su-Jin Yoo ◽  
In Seol Yoo ◽  
Jinhyun Kim ◽  
Seung Cheol Shim ◽  
...  

2020 ◽  
Author(s):  
Tomonari Suetsugu ◽  
Nobuhisa Matsuhashi ◽  
Hiroshi Tsuchiya ◽  
Takao Takahashi ◽  
Masahiro Fukada ◽  
...  

Abstract Background: Complete recovery from retroperitoneal squamous cell carcinoma of unknown primary site treated by multidisciplinary therapy is extremely rare.Case presentation: A 78-year-old man was referred to our hospital due to a mass measuring 8 cm in size in the left pelvic retroperitoneal area, which was diagnosed as a cancer of unknown primary site. The pathological type was squamous cell carcinoma. The left iliac artery/vein and ureter were involved in the tumor, and the tumor caused severe left leg pain. Although inflammation and symptoms were severe, palliative radiotherapy was considered. After that, biweekly combined therapy with docetaxel, cisplatin, and fluorouracil was planned. After 5 courses of chemotherapy, the tumor diameter reduced from 11.6 cm to 4 cm in size. In addition, the border between the iliac vessels, urinary tract and tumor became apparent. The patient underwent radical resection of the tumor 8 months after the treatment started. The left ureter and the external/internal iliac artery were preserved, but the external iliac vein was sacrificed because of the possibility of tumor invasion. The postoperative course was free of complications, and the patient was discharged 10 days after the operation. The histopathological findings showed no residual viable tumor cells or foreign body-type giant cells with necrosis. The pathological effect of chemotherapy was defined as Grade 3 (pathological complete response). The patient has experienced no recurrence or distant metastasis for 4 years.Conclusions: Multidisciplinary therapy succeeded in treating a retroperitoneal squamous cell carcinoma of unknown primary site with preservation of organ function.


Sign in / Sign up

Export Citation Format

Share Document